The failed CSU read removes a substantial value driver and raises risk for upcoming EVO756 AD data (Q3 2026). Monitor AD results closely; a second failure in a large indication would significantly impair pipeline value. The cash runway through 2028 provides a buffer, but without a clear near-term catalyst, downside pressure likely persists.
Price Chart
Executive Summary
Evommune announced top-line results from its Phase 2b trial of EVO756 in chronic spontaneous urticaria (CSU). The 160-patient trial did not meet the primary endpoint of mean change in UAS7 at 12 weeks at any dose. The company will cease development of EVO756 for CSU but continues development in atopic dermatitis and migraine. Management cited a 'strong cash position' supporting operations through 2028.
Key Facts
- Phase 2b trial enrolled 160 moderate-to-severe antihistamine-refractory CSU patients in the US, Europe, Canada and Japan.
- Study did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.
- Company plans to cease development of EVO756 for CSU.
- Company will continue to evaluate EVO756 in atopic dermatitis (Phase 2b data expected Q3 2026) and migraine prophylaxis (screening initiated).
- EVO301 (IL-18BP fusion protein) recently reported positive Phase 2a proof-of-concept data in atopic dermatitis.
- Anticipated cash runway through 2028.
Financial Impact
Phase 2b failure eliminates a key pipeline indication (CSU) for EVO756, a first-in-class oral MRGPRX2 antagonist. No financial figures disclosed beyond cash runway guidance.
Risk Factors
- Further clinical failure risk — EVO756 may fail in atopic dermatitis or migraine as well.
- Competitive risk from existing CSU therapies (omalizumab, ligelizumab) and AD pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-286918 |
| Document: evmn-ex99_1.htm | 0001193125-26-286918 |
| Document: 0001193125-26-286918-index-headers.html | 0001193125-26-286918 |
| Document: 0001193125-26-286918-index.html | 0001193125-26-286918 |
| Document: 0001193125-26-286918.txt | 0001193125-26-286918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers